Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0302）

Inclusion Criteria: 1. pathology diagnosed with advanced NSCL with measurable lesions; 2. Have failed for 2 lines of chemotherapy; 3. 18-70years,ECOG PS:0-2,Life expectancy of more than 3 months; 4. Other cytotoxic drugs,radiation therapy,or surgery≥4 weeks; 5. main organs function is normal; 6. must be agreed to take contraceptive measures during the study and within 6 months after end. Exclusion Criteria: 1. SCLC(including mixed with NSCLC); 2. the central cavity of Squamous cell carcinoma and hemoptysis with NSCLC; 3. patients failed to use the anti-tumor angiogenesis therapy; 4. patients has many influence factors toward oral medications ; 5. Brain metastases patients accompanied by symptoms or symptom control for less than two months; 6. patients with severe and failed to controlled diseases,including: suboptimal blood pressure control;suffering from myocardial ischemia or above grade I myocardial infarction, arrhythmias and Class I heart failure;activity or failure to control severe infections;liver disease such as cirrhosis, decompensated liver disease, chronic active hepatitis;poorly controlled diabetes (FBG)\>10mmol/L);urine protein≥++,etc. 7. patients failed to heal wounds or fractures for Long-term; 8. 4 weeks before enrollment, patients appeared NCI CTC AE grading \>1 pulmonary hemorrhage; 4 weeks before enrollment, patients who appeared NCI CTC AE grade\> 2 have other parts of the bleeding; patients has a tendency to bleed (eg active peptic ulcer) or are receiving thrombolytic or anticoagulant therapy such as warfarin, heparin or its analogues; 9. patients occurred venous thromboembolic events within 6 months; 10. patients has HIV-positive or organ transplantation;